AU2022245277B8 - Combination treatments for melanoma - Google Patents

Combination treatments for melanoma

Info

Publication number
AU2022245277B8
AU2022245277B8 AU2022245277A AU2022245277A AU2022245277B8 AU 2022245277 B8 AU2022245277 B8 AU 2022245277B8 AU 2022245277 A AU2022245277 A AU 2022245277A AU 2022245277 A AU2022245277 A AU 2022245277A AU 2022245277 B8 AU2022245277 B8 AU 2022245277B8
Authority
AU
Australia
Prior art keywords
inhibitor
months
immunotherapy
melanoma
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022245277A
Other languages
English (en)
Other versions
AU2022245277A9 (en
AU2022245277B1 (en
AU2022245277A1 (en
Inventor
Emma Jane Dean
Jeeyun Lee
Simon Andrew Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2022245277A1 publication Critical patent/AU2022245277A1/en
Publication of AU2022245277A9 publication Critical patent/AU2022245277A9/en
Publication of AU2022245277B1 publication Critical patent/AU2022245277B1/en
Application granted granted Critical
Publication of AU2022245277B8 publication Critical patent/AU2022245277B8/en
Priority to AU2025252564A priority Critical patent/AU2025252564A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022245277A 2021-03-26 2022-03-25 Combination treatments for melanoma Active AU2022245277B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025252564A AU2025252564A1 (en) 2021-03-26 2025-10-16 Combination treatments for melanoma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166295P 2021-03-26 2021-03-26
US63/166,295 2021-03-26
US202163208728P 2021-06-09 2021-06-09
US63/208,728 2021-06-09
PCT/EP2022/057895 WO2022200557A1 (en) 2021-03-26 2022-03-25 Combination treatments for melanoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025252564A Division AU2025252564A1 (en) 2021-03-26 2025-10-16 Combination treatments for melanoma

Publications (4)

Publication Number Publication Date
AU2022245277A1 AU2022245277A1 (en) 2023-11-02
AU2022245277A9 AU2022245277A9 (en) 2023-11-16
AU2022245277B1 AU2022245277B1 (en) 2025-07-17
AU2022245277B8 true AU2022245277B8 (en) 2025-08-07

Family

ID=81449142

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022245277A Active AU2022245277B8 (en) 2021-03-26 2022-03-25 Combination treatments for melanoma
AU2025252564A Abandoned AU2025252564A1 (en) 2021-03-26 2025-10-16 Combination treatments for melanoma

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025252564A Abandoned AU2025252564A1 (en) 2021-03-26 2025-10-16 Combination treatments for melanoma

Country Status (11)

Country Link
US (1) US20240197748A1 (https=)
EP (1) EP4313057A1 (https=)
JP (1) JP2024512558A (https=)
KR (1) KR20230162030A (https=)
AU (2) AU2022245277B8 (https=)
BR (1) BR112023019433A2 (https=)
CA (1) CA3213407A1 (https=)
IL (1) IL306028A (https=)
MX (1) MX2023011332A (https=)
TW (1) TW202304458A (https=)
WO (1) WO2022200557A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment
WO2025233224A1 (en) * 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015036499A1 (en) * 2013-09-11 2015-03-19 Medimmune Limited Anti-b7-h1 antibodies for treating tumors
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=3): Melanoma Patients Who Have Failed to IO)", CLINICALTRIALS.GOV, 18 December 2018 (2018-12-18), XP055935855, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/record/NCT03780608> [retrieved on 20220627] *

Also Published As

Publication number Publication date
IL306028A (en) 2023-11-01
WO2022200557A1 (en) 2022-09-29
KR20230162030A (ko) 2023-11-28
CA3213407A1 (en) 2022-09-29
AU2025252564A1 (en) 2025-11-27
MX2023011332A (es) 2023-10-03
JP2024512558A (ja) 2024-03-19
US20240197748A1 (en) 2024-06-20
EP4313057A1 (en) 2024-02-07
AU2022245277A9 (en) 2023-11-16
TW202304458A (zh) 2023-02-01
AU2022245277B1 (en) 2025-07-17
AU2022245277A1 (en) 2023-11-02
BR112023019433A2 (pt) 2023-10-24

Similar Documents

Publication Publication Date Title
EP4149455B1 (en) Combination of the atr inhibitor azd6738 and paclitaxel for use in treating melanoma in patients who previously received immunotherapy
EP1981539B1 (en) Treatment of metastatic breast cancer
AU2025252564A1 (en) Combination treatments for melanoma
CN117205312A (zh) 治疗癌症的卡博替尼与阿特珠单抗组合
CN119488588A (zh) 用于治疗子宫内膜癌的方法、组合物和组合
JP2022518236A (ja) 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体
KR20180101584A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료
CN109153722A (zh) 用于治疗癌症的方法
CN120731227A (zh) 使用抗ctla4抗体治疗结直肠癌的方法
JP2025134747A (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
JP2020511535A (ja) 中枢神経系（ｃｎｓ）がんを治療するためのプロテアソーム阻害剤の利用
CN119997973A (zh) 使用间充质上皮转化因子（met）靶向剂治疗非小细胞肺癌的方法
EA052375B1 (ru) Варианты комбинированного лечения меланомы
CN117098539A (zh) 用于黑色素瘤的组合治疗
TW202613164A (zh) 以抗IL-1β抗體治療化膿性汗腺炎之方法
TW202529760A (zh) 治療方法
WO2025212469A1 (en) Use of an immunoconjugate for the treatment of gastric cancer
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
EA053269B1 (ru) Способы лечения рака желчных протоков с применением антитела к pd-l1 в сочетании с химиотерапией
Smyth et al. Clinical Trial Registration: The trial is registered with www. ClinicalTrials. gov, identifier: NCT03443856.

Legal Events

Date Code Title Description
SREP Specification republished
TH Corrigenda

Free format text: IN VOL 59 , NO 29 , PAGE(S) 4077 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME ASTRAZENECA AB, APPLICATION NO. 2022245277, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 29.09.2022

FGA Letters patent sealed or granted (standard patent)